Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered,

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04734444` - SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue	N/A
Recruiting	`NCT01837862` - A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas	Phase 1/Phase 2
Recruiting	`NCT06104488` - A Study of Avutometinib for People With Solid Tumor Cancers	Phase 1
Completed	`NCT04659421` - Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas	Phase 2
Recruiting	`NCT04174820` - Child's Study of the Impact of PF Lesion on Motor Skills, Language, Cognitive Functioning and Social Cognition
Completed	`NCT02197637` - Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma	Phase 2
Completed	`NCT05373394` - Evaluation of Cognitive and Motor Neurological Disorders in the Short and Long Term After Surgery for the Removal of a Diffuse Low-grade Glioma of the Supplementary Motor Area
Recruiting	`NCT05406700` - Niraparib In Recurrent IDH 1/2 Gliomas	Early Phase 1
Active, not recruiting	`NCT04865315` - A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors
Recruiting	`NCT06159478` - Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)	Phase 2
Recruiting	`NCT06381570` - Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas	Early Phase 1
Terminated	`NCT03763422` - Trial in Low Grade Glioma Patients: Wait or Treat	Phase 3
Completed	`NCT04346472` - Longitudinal MRI Assessment in Patients With Diffuse Low-grade Gliomas
Active, not recruiting	`NCT03948490` - Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas	N/A
Recruiting	`NCT04923126` - SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma	Phase 1/Phase 2
Completed	`NCT00782626` - Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas	Phase 2
Completed	`NCT05873946` - Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery
Not yet recruiting	`NCT05555550` - Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG	Early Phase 1
Withdrawn	`NCT05233215` - GROW (Glioma Specialists Reaching Out With Support) Support	N/A
Completed	`NCT01497860` - Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas	Phase 2

NCT number	NCT05760586
Study type	Expanded Access
Source	Day One Biopharmaceuticals, Inc.
Contact	WEP Clinical
Phone	919-694-5088
Email	day101eap@wepclinical.com
Status	Available
Phase

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms